Trump also learned to "4 plus 7" drug prices drop 95 percent?

Comprehensive: dandelion - Rain Xuandisobedient, I look next door to Canada imports, see you do not reduce prices?December 18, 2019, the FDA's website published a "The Trump administration takes historic steps to reduce the price of prescription drugs in the United States."Trump took historic steps to lower u.Sprescription drug prices
the Trump administration's proposed regulations would allow the import of certain prescription drugs from Canada, and the administration announced that it would provide the industry with a new draft guideline that describes procedures that drug manufacturers can follow to facilitate faster imports of prescription drugs and biological productsNews reported that president Trump today issued a notice with the U.SDepartment of Health and Human Services (HHS) and the U.SFood and Drug Administration (FDA) on the proposed regulation that, if finalized, would allow the import of certain prescription drugs from CanadaNPRM is the first step in implementing federal law that would allow certain prescription drugs to be imported from Canada under certain conditions to ensure that the import does not pose additional risks to public health and safety, while significantly reducing the cost of the drug to U.Sconsumersintroduced competition, with price cuts of more than 95 per cent, comparable to China's "4 plus 7"and just a few days ago (December 13), the FDA website published another "generic drug competition and drug prices" research article, the study used the first generic drugs from 2015 to 2017, the results of price and competition analysis, the results show that in the introduction of six or more competitors, the price reduction of more than 95%, which is the largest purchase in China 4 plus 7studies have shown that the initial entry of generic drugs into the market will bring greater competition, resulting in lower generic priceschart: The price of generic drugs and drug pricesthe ordinates are the median ratio of generic sands to branded drugs, and horizontal coordinates are the number of generic drug manufacturersresults show:for products with only a single generic drug manufacturer, the average generic manufacturer's price is 39% lower than the average manufacturer price of the brand before the generic stakes, while the invoice price is 31% loweraverage manufacturer price data show that in the case of two competitors, generics are 54 per cent cheaper than previous lyse-branded drugs, compared with 44 per cent when using invoice-based drug pricesaverage manufacturer price data show that in the case of four competitors, generics prices were 79 per cent lower than those of pre-generic selling drugs, compared with 73 per cent when using invoice-based drug pricesa generic price of more than 95% compared to the brand price using the average manufacturer's price and invoice price, in the case of six or more competitorsall competing categories, we found that generics using the average manufacturer's price in the sample had a median price of 40% relative to the brandthe study was based on price information from two sources:Average Manufacturer Price (AMP): The price is reported to the Centers for Medicare and Medicaid Services (CMS), andinvoice-based wholesale price: the price reflects pharmacy price information from IQVIA's National Sales View databasehas introduced a new draft guide to expedite imports
in addition, the authorities announced that they will provide the industry with a new draft guide that describes the procedures that drug manufacturers can follow to facilitate the accelerated import of prescription drugs and biological productsthe draftguidelines describe the procedures for drug manufacturers to submit documents that prove that drugs imported from other countries are in fact FDA-approved varieties, including products manufactured in the form of FDA approvalThese drugs are FDA approved, manufactured abroad, approved for sale in other countries, and originally planned to be sold in other countriesNPRM will allow states and some other non-federal entities to submit proposals for import plans to the FDA for review and authorizationimport programs may be co-financed by pharmacists, wholesalers, or other state or non-federal entitiesThese procedures, known as Section 804 Import Programs, will be authorized by the FDA to regulate the import of certain prescription drugs that are already approved in Canada and are eligible for FDA approval qualified prescription drugs must be relabeled as required until imported, and tests for authenticity and degradation (degradation), especially to ensure that they meet established specifications and standards noteworthy, the draft guidelines describe procedures that drug manufacturers should follow to obtain certain FDA-approved prescription drugs, including biological products, that were originally manufactured abroad and intended to be sold abroad Additional drug approvals through these procedures will provide pharmaceutical companies with greater flexibility to offer these products at prices lower than required by their current distribution contracts draft guidelines also recommend that drug manufacturers include statements in product labels and prescription information to help pharmacists accurately identify, distribute, and bill these products Prescription drugs (including biological products) imported in accordance with the routes described in the draft guidelines may be available to patients in a variety of settings, including hospitals, health care providers' offices, or U.S.-licensed pharmacies.